Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02484170
Other study ID # H15-01260
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 30, 2015
Est. completion date April 30, 2017

Study information

Verified date October 2018
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

30% mannitol cream has shown its ability to reduce the activation of the Capsaicin (TRPV1) (Transient Receptor Potential Vanilloid 1) receptor, a likely cause of the pain of post-herpetic neuralgia (PHN). This randomized placebo-controlled crossover study compares PHN pain one week before, for one week on the randomly assigned mannitol versus placebo cream and, after a three day washout, for one week on the other cream. Following this crossover study, participants receive mannitol cream for three months. Pain levels will be checked to assess whether continued use of this cream significantly reduces the pain levels associated with PHN. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month following which their pain levels will be checked.


Description:

Pain levels: 0 to 10 Numerical Rating Scale (NRS), medication and alcohol intake will be checked daily for one week prior to randomization in 20 participants with post herpetic neuralgia, lasting more than three months. Following this 10 will be randomized to apply 30% mannitol in vehicle cream and 10 to apply vehicle cream alone for one week during which daily pain levels and use of medication and alcohol will be measured together with the mode of application (rubbing in or applying it to cling wrap then applying the cream coated cling wrap to the skin in cases of severe allodynia). After a three day washout period, they will be given the cream they did not receive previously for one week. The same variables will be recorded daily. The data collected in the first 24 days will be used to generate a power analysis. Following this, all subjects will receive the 30% mannitol cream to apply for three months. Their pain levels, medication intake and method of application will be measured once a month for three months. T-tests will compare the pain levels for mannitol and placebo users before and after one week of the use of each cream to see if the mannitol cream provides better short term pain relief than placebo. Repeated measures ANOVA (Analysis Of VAriance) will compare pain levels before using the mannitol cream and monthly for three months to assess the long-term effects of mannitol cream. Variables collected at each visit, which will not be used for statistical purposes in the current very small pilot project but may be used in a later study, include: application method, effect and side effects of the cream, medication and alcohol use, PHQ - 9 (Personal Health Questionnaire, 9 questions), and questions from the brief pain inventory score. At three months, a satisfaction score will be added to the database. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month, following which their pain levels, PHQ - 9 and brief pain inventory scores will be checked.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date April 30, 2017
Est. primary completion date April 29, 2016
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria

1. - Suffering from post-herpetic neuralgia on the trunk or the extremities for at least three months.

2. - Maximum daily pain score greater than or equal to 5/10.

3. - Having failed to improve with at least one neuropathic pain medication.

4- Able and willing to fill a fluid survey NRS pain scale and a medication intake questionnaire daily, preferably online but on paper, if unable, for the first 24 days of the study, then once a month for three months..

5 - Preferably have access to someone who can apply cream to their back if they have pain in the back and cannot reach the area.

6 - If that is not possible, ability to apply the cream to their own back, using an applicator which will be supplied.

Exclusion Criteria:

1. Allergies to any of the ingredients of the cream

2. Open lesions or abrasions on the skin where the cream will be applied

3. Using corticosteroids

4. Unwilling to stop using other topical products (creams or patches) for the treatment of post-herpetic neuralgia

5. Pregnant, breast-feeding or not using birth control

6. Suffering from severe chronic pain from a cause other than post-herpetic neuralgia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mannitol cream
Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
Placebo
Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study

Locations

Country Name City State
Canada Dr. Helene Bertrand Inc. North Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Bertrand H, Kyriazis M, Reeves KD, Lyftogt J, Rabago D. Topical Mannitol Reduces Capsaicin-Induced Pain: Results of a Pilot-Level, Double-Blind, Randomized Controlled Trial. PM R. 2015 Nov;7(11):1111-7. doi: 10.1016/j.pmrj.2015.05.002. Epub 2015 May 12. — View Citation

Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015 Apr;90(4):532-45. doi: 10.1016/j.mayocp.2015.01.018. Review. — View Citation

Shannon HJ, Anderson J, Damle JS. Evidence for interventional procedures as an adjunct therapy in the treatment of shingles pain. Adv Skin Wound Care. 2012 Jun;25(6):276-84; quiz 285-6. doi: 10.1097/01.ASW.0000415345.22307.f3. Review. — View Citation

Szolcsányi J, Sándor Z. Multisteric TRPV1 nocisensor: a target for analgesics. Trends Pharmacol Sci. 2012 Dec;33(12):646-55. doi: 10.1016/j.tips.2012.09.002. Epub 2012 Oct 12. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in worst NRS (Numerical Rating Scale) pain score In the last 24 hours, how bad was your pain at its worst? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Primary Change in average NRS (Numerical Rating Scale) pain score In the last 24 hours, how bad was your pain on average? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Secondary Change in Pain medication intake Number of pills taken for pain in one day. Will decrease as the pain intensity decreases. Write the number of tablets that you took: 1. Tylenol/acetaminophen______, 2. Anti-inflammatory medication like Advil/ibuprofen, naproxen, diclofenac, Voltaren, Aleve______, 3. Tylenol or ASA (acetylsalicylic acid) plus narcotic like Tylenol 3, or 292 or Tramacet (acetaminophen/tramadol) ______, 4. Narcotic like morphine, hydromorphone/dilaudid, fentanyl, Demerol, tramadol______, 5. Cannabis, marijuana, or pot______, The total in each category will be added to calculate the total number of tablets taken in 24 hours. Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3,months
Secondary Change in Alcohol intake Number of alcoholic drinks in one day. May decrease as the pain intensity decreases. Write down the total number of alcoholic drinks you had in the last 24 hours:how many glasses of wine ______ glasses of hard liquor______ bottles of beer______. The total number of glasses will be recorded. Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Secondary Change in questions from the brief pain inventory score The total from the following questions will be recorded to measure how much their pain is interfering with their lives: Circle one number. In the last 24 hours, how much has your pain interfered with your:
General activity:, Mood: Walking ability: Normal work: (includes both work outside the home and housework) Relations with other people: Sleep: Enjoyment of life: Each of these will be scored as follows: does not interfere 0 1 2 3 4 5 6 7 8 9 10 completely interferes. The scores added up. This sum should decrease as the pain decreases.
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Secondary Change in PHQ-9 (Personal health questionnaire, 9 questions) Score Patients will fill the PHQ - 9 score. http://phqscreeners.com/pdfs/02_PHQ-9/English.pdf The sum of the answers from this questionnaire, which is used to measure the degree of depression, may decrease as the pain intensity decreases. Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Secondary Change in Method of cream application Patients will describe whether they use cling wrap (4), gentle applicator (3) or rubbing in gently (2) or vigourous rubbing (1) when each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months
Secondary Change in effect and side effects of the cream How many times did you apply the cream today?_______ Circle one number. How bad was your pain?.. Before you applied the cream? NRS 0-10 1hour after you applied the cream? NRS 0-10 Did the cream relieve your pain? No ? if Yes ? in how many minutes?____ For how many hours was your pain relieved?____ Did you experience a side effect from the cream? No ? if Yes ? What was it?_________________ Any comments?_______________________ Daily for the 14 days, of the crossover study, then at 1,2 and 3 months
Secondary Satisfaction from cream use How satisfied were you with the use of this cream? Not at all satisfied 0 1 2 3 4 5 6 7 8 9 10 extremely satisfied Three months after use of mannitol cream was started.
Secondary Change in pain score from mannitol cream use to mannitol and menthol cream use Maximum pain score after 3 months of mannitol cream use compared to maximum pain score after one month of mannitol and menthol cream use 1st measurement Three months after use of mannitol cream was started 2nd measurement one month after mannitol and menthol cream started
See also
  Status Clinical Trial Phase
Terminated NCT00964990 - A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) Phase 2
Completed NCT00394901 - A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia Phase 3
Completed NCT01252160 - Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage Phase 4
Completed NCT00377598 - Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia Phase 2/Phase 3
Completed NCT00160667 - A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Phase 2
Terminated NCT00245544 - Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004) Phase 2
Completed NCT00335933 - Safety and Efficacy of Gabapentin in Postherpetic Neuralgia Phase 3
Completed NCT00617461 - A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment Phase 2
Withdrawn NCT02426411 - Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN Phase 2
Completed NCT01129531 - A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia Phase 2
Completed NCT00674687 - A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing N/A
Terminated NCT01678924 - A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia Phase 2
Completed NCT00424372 - A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia Phase 3
Completed NCT00619476 - A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) Phase 2
Terminated NCT00295776 - Lamictal in the Treatment of Post-Herpetic Neuralgia Phase 2/Phase 3
Completed NCT00570310 - Neuropathic Pain Syndrome Patient Study (MK-0000-072) Phase 1
Terminated NCT00282763 - A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) Phase 2
Completed NCT00568321 - RN624 For Pain Of Post-Herpetic Neuralgia Phase 2
Not yet recruiting NCT01102101 - Effect of Opioids in Neuropathic Pain in Postherpetic Patients Phase 3
Completed NCT00614705 - PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia Phase 2